Recent advances in systemic therapy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huajun, Zhang, Wuyang, Jiang, Longying, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744248/
https://www.ncbi.nlm.nih.gov/pubmed/35000616
http://dx.doi.org/10.1186/s40364-021-00350-4
_version_ 1784630078006624256
author Zhang, Huajun
Zhang, Wuyang
Jiang, Longying
Chen, Yongheng
author_facet Zhang, Huajun
Zhang, Wuyang
Jiang, Longying
Chen, Yongheng
author_sort Zhang, Huajun
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic drug that has been proven to be clinically effective for treating advanced HCC. However, over the past three years, the rapid progress of molecular targeted therapies has dramatically changed the treatment landscape for advanced HCC. Immune checkpoint therapies are now being incorporated into HCC therapies, and their combination with molecular targeted therapy is emerging as a tool to enhance the immune response. In this review, we summarize the development and progress of molecular targeted agents and immunotherapies in HCC.
format Online
Article
Text
id pubmed-8744248
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87442482022-01-11 Recent advances in systemic therapy for hepatocellular carcinoma Zhang, Huajun Zhang, Wuyang Jiang, Longying Chen, Yongheng Biomark Res Review Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic drug that has been proven to be clinically effective for treating advanced HCC. However, over the past three years, the rapid progress of molecular targeted therapies has dramatically changed the treatment landscape for advanced HCC. Immune checkpoint therapies are now being incorporated into HCC therapies, and their combination with molecular targeted therapy is emerging as a tool to enhance the immune response. In this review, we summarize the development and progress of molecular targeted agents and immunotherapies in HCC. BioMed Central 2022-01-09 /pmc/articles/PMC8744248/ /pubmed/35000616 http://dx.doi.org/10.1186/s40364-021-00350-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhang, Huajun
Zhang, Wuyang
Jiang, Longying
Chen, Yongheng
Recent advances in systemic therapy for hepatocellular carcinoma
title Recent advances in systemic therapy for hepatocellular carcinoma
title_full Recent advances in systemic therapy for hepatocellular carcinoma
title_fullStr Recent advances in systemic therapy for hepatocellular carcinoma
title_full_unstemmed Recent advances in systemic therapy for hepatocellular carcinoma
title_short Recent advances in systemic therapy for hepatocellular carcinoma
title_sort recent advances in systemic therapy for hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744248/
https://www.ncbi.nlm.nih.gov/pubmed/35000616
http://dx.doi.org/10.1186/s40364-021-00350-4
work_keys_str_mv AT zhanghuajun recentadvancesinsystemictherapyforhepatocellularcarcinoma
AT zhangwuyang recentadvancesinsystemictherapyforhepatocellularcarcinoma
AT jianglongying recentadvancesinsystemictherapyforhepatocellularcarcinoma
AT chenyongheng recentadvancesinsystemictherapyforhepatocellularcarcinoma

Ejemplares similares